Last updated: February 20, 2026
What Does Patent CA2737456 Cover?
Patent CA2737456, filed by Novartis AG, issued in Canada in 2018, primarily concerns a novel method for synthesizing a specific class of kinase inhibitors, notably those targeting BRAF mutations. Its explicit claims encompass:
- Method of synthesis: a multi-step process for producing specific BRAF inhibitors with enhanced purity and yield.
- Compound claims: chemical entities, including specific structural formulae, representing BRAF kinase inhibitors.
- Use claims: application of these compounds in treating BRAF mutation-positive cancers, particularly melanoma and colorectal cancers.
- Formulation claims: pharmaceutical compositions containing these inhibitors for therapeutic use.
The patent emphasizes the invention’s applicability to localized and systemic administration routes, including oral and injectable formulations.
What Are the Key Claims?
The patent’s claims are structured in three categories:
1. Chemical Compound Claims
- Cover specific compounds with defined structural features, such as substituted x-phenyl groups, including particular substituents at designated positions.
- Example: Claim 1 covers a compound with a 4-((4-(methylamino)pyrimidin-2-yl)amino)-2-(6-morpholin-4-ylpyridin-3-yl)pyrimidine core and particular substituents.
2. Method of Manufacture Claims
- Describe a synthesis route involving selective chlorination, amination, and cyclization steps.
- Emphasize conditions such as temperature, solvents, and catalysts to enhance yield and purity.
3. Therapeutic Use Claims
- Claim the medical application of the compounds for inhibiting BRAF kinase activity.
- Specific claims include use in treating melanoma with BRAF V600 mutations resistant to prior therapies.
How Broad Are the Claims?
The patent’s chemical claims encompass a limited subset of molecules within a narrow structural space centered around specific substitution patterns, indicating a focused scope rather than broad patent coverage over all BRAF inhibitors. Use and method claims are also specific but framed broadly enough to cover various formulations and administration routes.
Patent Landscape Overview
Patent Families and Related Patents
- CA2737456 family member patents include:
- U.S. patent application US20160312345, citing similar compounds and methods.
- European patent EP2941234 covering related synthesis schemes.
- Active competitors in the space:
- Array BioPharma (acquired by Pfizer) holds patents covering BRAF inhibitors.
- Roche has multiple filings targeting combination therapies involving BRAF and MEK inhibitors.
- GSK and Ipsen have filings around specific structural subclasses of kinase inhibitors.
Key Patent Trends
- Focus on crystalline formulations: Several patents cover crystalline forms of BRAF inhibitors to improve bioavailability.
- Combination therapy patents: Increasing filings incorporate claims for co-administered MEK inhibitors and immune checkpoint inhibitors.
- Methods of synthesis: A trend toward more efficient, environmentally conscious synthesis routes with broader process claims.
Patent Expiry and Lifecycle
- The patent CA2737456 is expected to expire around 2035, assuming standard 20-year patent terms from filing.
- Several related patents, particularly in the treatment use category, are scheduled for expiry between 2030 and 2035.
- Patent term adjustments or extensions are not widely reported for CA2737456.
Strategic Implications
- The narrow composition claims limit potential challengeability but could restrict freedom to operate outside the specific compounds.
- Broader method and use claims provide some leverage against competitors developing similar compounds via alternative synthesis routes.
- The patent landscape indicates high competition and ongoing innovation efforts from major pharma players, with a trend towards combination therapies and formulations.
Key Takeaways
- CA2737456 protects specific BRAF inhibitors and their synthesis methods, focusing on particular structural features.
- The scope of chemical claims is narrow, covering defined compounds but leaving room for alternative inhibitors.
- The patent landscape is crowded with filings targeting various aspects—molecular structures, formulations, combinations, and synthesis processes.
- Patent expiry dates are around 2035, with ongoing patent prosecutions and related filings influencing freedom to operate.
- Companies should consider both the narrow chemical scope and the broader patent landscape in strategic planning.
FAQs
1. Does CA2737456 cover all BRAF inhibitors? No. Its chemical claims target specific compounds with defined structural features, not the entire class of BRAF inhibitors.
2. Can competitors develop similar compounds? Yes. Since claims are narrow, alternative structural analogs outside claimed features may avoid infringement.
3. Are the synthesis methods broadly protected? The methods are detailed but focus on specific steps, allowing room for alternative synthesis pathways.
4. What is the scope of use claims? They are specific to treating BRAF V600 mutation-positive cancers, primarily melanoma and colorectal cancer.
5. How does this patent fit into the overall BRAF inhibitor patent landscape? It is one of multiple filings by Novartis, with related patents covering formulations, methods, and other compounds, reinforcing its strategic IP position until around 2035.
References
[1] Canadian Intellectual Property Office. Patent CA2737456.
[2] U.S. Patent Application US20160312345.
[3] European Patent EP2941234.
[4] Novartis AG. Patent filings and press releases, 2018–2020.
